Search

Your search keyword '"Saleh Alkhalifah"' showing total 2 results
Start Over Author "Saleh Alkhalifah" Journal journal of infection and public health
2 results on '"Saleh Alkhalifah"'

1. Favipiravir versus standard of care in patients with severe COVID-19 infections: A retrospective comparative study

Author

Zainab Almoosa, Mustafa Saad, Samer Qara, Mahmoud Mustafa, Ali Mansour, Duaa Alshab, Jehad Alhashem, Sajida ALKhawajah, Saleh Alkhalifah, Mokhtar ALmarzooq, Mohammed ALzain, Neda’a Anshasi, Gasmelseed Ahmed, and Abbas Al Mutair

Subjects
Favipiravir, COVID-19, SARS-CoV-2, Pneumonia, Antiviral therapy and standard therapy, Infectious and parasitic diseases, RC109-216, Public aspects of medicine, RA1-1270
Abstract

Objective: To assess the efficacy of Favipiravir compared to the standard therapy in treating patients with severe COVID-19 infection. Methods: This is a retrospective cohort of patients with COVID-19 pneumonia who were treated with favipiravir, versus comparison group that received the standard of care. Results: A total of 226 patients were included; 110 patients received favipiravir and 116 patients received standard of care. Patients who received favipiravir had longer time to recovery (14.2 ± 8.8 versus 12.8 ± 5.2, p = 0.17). Favipiravir was associated with an improved early day 14 mortality (4 [3.6%] versus 11 [9.5%]), p = 0.008), but was associated with a higher day 28 mortality (26 [23.6%] versus 11 [9.5%], p = 0.02). The overall mortality was higher in the favipiravir versus the standard of care group but difference was not statistically significant (33 [30.0%] versus 24 [20.7%], p = 0.10). Conclusion: The addition of favipiravir to standard of care was not associated with any improvement in clinical outcomes or mortality. Larger randomized controlled clinical trials are needed to further assess the efficacy of favipiravir.

Published
2021
Full Text
View/download PDF

2. Favipiravir versus standard of care in patients with severe COVID-19 infections: A retrospective comparative study

Author

Samer Qara, Mustafa Saad, Jehad Alhashem, Ali Mansour, Mahmoud Mustafa, Gasmelseed Y. Ahmed, Zainab Almoosa, Mohammed ALzain, Duaa Alshab, Neda’a Anshasi, Sajida ALKhawajah, Mokhtar ALmarzooq, Saleh Alkhalifah, and Abbas Al Mutair

Subjects
medicine.medical_specialty, Standard of care, Coronavirus disease 2019 (COVID-19), Infectious and parasitic diseases, RC109-216, Favipiravir, Antiviral Agents, Internal medicine, Medicine, Antiviral therapy and standard therapy, Humans, In patient, Retrospective Studies, business.industry, SARS-CoV-2, Public Health, Environmental and Occupational Health, COVID-19, Retrospective cohort study, Standard of Care, General Medicine, Pneumonia, medicine.disease, Amides, Clinical trial, Infectious Diseases, Treatment Outcome, Pyrazines, Original Article, Public aspects of medicine, RA1-1270, business, Standard therapy
Abstract

Objective To assess the efficacy of Favipiravir compared to the standard therapy in treating patients with severe COVID-19 infection. Methods This is a retrospective cohort of patients with COVID-19 pneumonia who were treated with favipiravir, versus comparison group that received the standard of care. Results A total of 226 patients were included; 110 patients received favipiravir and 116 patients received standard of care. Patients who received favipiravir had longer time to recovery (14.2 ± 8.8 versus 12.8 ± 5.2, p = 0.17). Favipiravir was associated with an improved early day 14 mortality (4 [3.6%] versus 11 [9.5%]), p = 0.008), but was associated with a higher day 28 mortality (26 [23.6%] versus 11 [9.5%], p = 0.02). The overall mortality was higher in the favipiravir versus the standard of care group but difference was not statistically significant (33 [30.0%] versus 24 [20.7%], p = 0.10). Conclusion The addition of favipiravir to standard of care was not associated with any improvement in clinical outcomes or mortality. Larger randomized controlled clinical trials are needed to further assess the efficacy of favipiravir.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results